PROFILPELAJAR.COM

H5N8 vaccine
Vaccine description
Target	H5N8
Vaccine type	Inactivated
Clinical data
Trade names	Zoonotic Influenza Vaccine Seqirus
Routes of; administration	Intramuscular
ATC code	J07BB02 (WHO) ;
Legal status
Legal status	EU: Rx-only;

An H5N8 vaccine is an influenza vaccine intended to provide acquired immunity against H5 subtype influenza A viruses.^[1] It is given via Intramuscular injection.^[1]

Zoonotic influenza vaccine Seqirus

Zoonotic influenza vaccine Seqirus is authorized for use in the European Union.^[1] It contains a flu strain called A/Astrakhan/3212/2020 (H5N8)-like strain (CBER-RG8A) (clade 2.3.4.4b).^[1] Zoonotic influenza vaccine Seqirus was considered to be the best candidate to provide protection against circulating H5 influenza A strains.^[1]

The most common side effects include reactions at the site of injection (swelling, pain, redness and hardening of the skin), myalgia (muscle pain), headache, tiredness, chills and feeling generally unwell.^[1]

Zoonotic Influenza Vaccine Seqirus H5N8 is indicated for active immunization against H5 subtype influenza A viruses in adults 18 years of age and older.^[1]

Society and culture

The European Commission arranged for a supply of zoonotic influenza vaccine.^[2]

References

^ ^a ^b ^c ^d ^e ^f ^g ^h "Zoonotic Influenza Vaccine Seqirus EPAR". European Medicines Agency (EMA). 9 October 2023. Retrieved 26 September 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ "Commission secures access to 665,000 doses of zoonotic influenza vaccines". European Commission (Press release). 11 June 2024. Retrieved 26 September 2024.